Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director John Ackerman Sells 201,303 Shares

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) Director John Ackerman sold 201,303 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total transaction of $4,058,268.48. Following the transaction, the director now owns 149,794 shares of the company's stock, valued at approximately $3,019,847.04. This represents a 57.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

John Ackerman also recently made the following trade(s):

• On Tuesday, May 27th, John Ackerman sold 1,084,276 shares of Guardian Pharmacy Services stock. The stock was sold at an average price of $20.16, for a total transaction of $21,859,004.16.

Guardian Pharmacy Services Trading Up 2.3%

Guardian Pharmacy Services stock traded up $0.49 during trading hours on Tuesday, reaching $21.78. 290,686 shares of the stock were exchanged, compared to its average volume of 169,453. Guardian Pharmacy Services, Inc. has a twelve month low of $14.16 and a twelve month high of $26.91. The stock has a 50 day moving average of $23.19 and a two-hundred day moving average of $22.01.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). The firm had revenue of $329.31 million for the quarter, compared to the consensus estimate of $321.21 million. On average, analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on GRDN shares. Raymond James set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. Truist Financial reissued a "buy" rating and issued a $28.00 price objective (up previously from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th. Finally, Wall Street Zen lowered shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. increased its stake in shares of Guardian Pharmacy Services by 4.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 12,010 shares of the company's stock valued at $243,000 after acquiring an additional 564 shares in the last quarter. LPL Financial LLC grew its position in Guardian Pharmacy Services by 4.8% in the 4th quarter. LPL Financial LLC now owns 17,679 shares of the company's stock valued at $358,000 after purchasing an additional 807 shares during the period. GAMMA Investing LLC purchased a new position in Guardian Pharmacy Services during the 1st quarter worth $170,000. Lazard Asset Management LLC boosted its holdings in Guardian Pharmacy Services by 0.5% during the 4th quarter. Lazard Asset Management LLC now owns 190,797 shares of the company's stock worth $3,865,000 after acquiring an additional 860 shares during the last quarter. Finally, R Squared Ltd purchased a new position in Guardian Pharmacy Services during the 4th quarter worth $30,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.